Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis. Here we describe the profile of ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. In vivo, this compound did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models. ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.
Figure 1. Identification of novel small molecule Plk1 inhibitor
A: Structure of the Plk1 inhibitor ON01910. B: Plk1 inhibitory activity of ON01910. Ten nanograms of recombinant Plk1 was mixed with different concentrations of ON01910 and kinase assays performed as described in the Experimental Procedures using recombinant Cdc25C or casein as substrates. The reaction mixtures were subjected to SDS-PAGE and autoradiography. C: Plk1 assays were performed as described in B, and the reactions spotted onto strips of P81 phosphocellulose paper, washed, and counted. The values from individual samples were analyzed and plotted as a function of drug concentration using Prism 4 Graphpad software. D: Inhibition of mammalian Plk1 activity by ON01910. A synchronized population of HeLa cells at the midmitotic phase was used for the preparation of cell lysates and Plk1 immunoprecipitated from the clarified cell lysates as described in the Experimental Procedures. The precipitates were washed and the kinase assays performed in the presence of increasing concentrations of ON01910 as described in B using recombinant Cdc25C or casein as substrates.
anti-sense oligonucleotides (Spankuch-Schmitt et al., 2002b) , says performed using Casein or Cdc25C as substrates. SDS-PAGE analysis of the reaction mixture showed that ON01910 or small interfering RNAs (Spankuch-Schmitt et al., 2002a, Liu and Erikson, 2003) results in mitotic arrest characterized by is a potent inhibitor of Plk1 ( Figure 1B ). To determine the IC 50 values, Plk1 assays were performed as described above, and spindle abnormalities and apoptosis. In contrast to Plk1, other members of this family, such as Plk3, appear to function as the reaction mixture spotted onto strips of P81 phosphocellulose paper, washed, and counted. The values from individual growth suppressor genes (Dai and Cogswell, 2003; Conn et al., 2000) , as suggested by their lack of expression in tumor tissamples were analyzed and plotted as a function of inhibitor concentration using Prism 4 Graphpad software for Macintosh. sues (Dai and Cogswell, 2003) . Consistent with its role as a growth suppressor gene, ectopic overexpression of Plk3, but These studies revealed that ON01910 inhibits Plk1 with an IC 50 of 9-10 nM. To ascertain that this inhibition was not restricted not that of a kinase-defective mutant, caused growth arrest and apoptosis of normal fibroblasts (Dai and Cogswell, 2003) .
to recombinant Plk1, we examined the effects of ON01910 on the enzyme activity of Plk1 immunoprecipitated from a synHere, we describe the profile of ON01910, a small molecule inhibitor of Plk1 that induces mitotic arrest in a wide range of chronized population of HeLa cells at midmitotic phase. Kinase assays performed with these immunoprecipitates ( Figure 1D ) tumor cells, characterized by spindle abnormalities leading to apoptotic death. This compound, which exhibits very little or again showed that ON01910 is a potent inhibitor of HeLa cellderived Plk1, and the degree of inhibition seen with this preno toxicity, was found to be a potent inhibitor of tumor growth in several animal models, and showed a high degree of synerparation was similar to that seen with recombinant Plk1. It is interesting to note that when Cdc25C was used in these asgism with several chemotherapeutic agents currently used in cancer therapy, often inducing complete regression of tumors.
says as a substrate, a residual level of phosphorylation was seen even in the presence of 1 µM ON01910, suggesting the existence of a residual level of kinase activity in the immunoResults precipitates that is insensitive to ON01910. This may be due to contaminating kinases such as Chk1/2, which are known to Derivation of a small molecule inhibitor of Plk1 We have recently described the synthesis of a family of novel interact with Plk1 and are capable of phosphorylating Cdc25C. We could also demonstrate the inhibition of Plk1 by ON01910 small molecule kinase inhibitors that are unrelated to ATP (Reddy and Reddy, 2002a; Reddy and Reddy, 2002b ; Reddy using a commercially available ELISA-based assay kit, the results of which are presented in Supplemental Figure S1 . and Reddy, 2003) or other purine and pyrimidine nucleosides, and which exhibit potent antitumor activity. Screening of this novel library of molecules for antitumor activity using cell bioSteady-state kinetic analysis of Plk1 inhibition by ON01910 logical assays yielded several candidate molecules that appeared to induce mitotic arrest of tumor cells. Further analysis
To define the biochemical mechanism of action of ON01910, we examined the effects of increasing concentrations of ATP of these selected group of molecules for inhibitors of Plk1 activity led to the identification of one compound, ON01910 (Fig- or substrate on the inhibitory activity of the compound using steady-state analysis. Ten nanograms of recombinant Plk1 was ure 1A), that had the most potent inhibitory activity. For these assays, 10 ng of recombinant Plk1 was mixed with different mixed with different concentrations of ON01910 and incubated at room temperature, followed by the addition of a reaction concentrations of ON01910 or DMSO (control) and kinase as- A: Ten nanograms of recombinant Plk1 was mixed with different concentrations of ON01910 and kinase assays performed in the presence of varying concentrations of ATP as described in Figure 1C . The values from individual samples were analyzed and plotted as a function of inhibitor concentration using Prism 4 Graphpad software. B: Representative Michaelis-Menton curves with curve fit derived by nonlinear regression are shown. C and D: IC 50 curves (C) and Michaelis-Menton curves (D) for Plk1 in the presence of varying concentrations of Cdc25C substrate and ON01910 were generated as described in A and B.
mixture containing γ
32

P-ATP and varying concentrations of
We next examined the inhibitory effects of ON01910 on a panel of serine/threonine and tyrosine kinases. These studies ATP. Following termination of the reaction, the reaction mixture was spotted onto phosphocellulose strips, which were washed showed that at slightly higher concentrations, ON01910 exhibits inhibitory activity against three other kinases tested, the and counted. The values from individual samples were analyzed and plotted as a function of inhibitor concentration using PDGF receptor (PDGFR), Abl, and Flt-1. At 10-to 20-fold higher concentrations, we also observed inhibition of CDK1, Plk2, Src, Prism 4 Graphpad software (Figure 2A) , and values for K m (1.988 µM) and V max (76.72 µM/min/mg protein) were obtained and Fyn (Supplemental Table S1 ). These results suggest a common feature shared between these kinases in their subby fitting the data to the Michaelis-Menton equation (Cleland, 1977) (Figure 2B ). These analyses showed that the velocity of strate binding sites. Of these different kinases, ON01910 was most active against Plk1, which is likely to be its primary target. substrate phosphorylation was unaltered in the presence of increasing concentrations of ATP, and the IC 50 values for the inhibitor remained between 9 and 10 nM, suggesting that
In vivo effects of ON01910 on Plk1 activity Because inhibition of Plk1 synthesis or activity induced tumor ON01910 is not an ATP-competitive inhibitor. We next examined the effects of increasing concentrations of substrate on cell death preceded by mitotic catastrophe (Reviewed in Dai and Cogswell, 2003) , it was of interest to test the effect of the inhibitory activity of the compound in the presence of a constant amount of ATP (100 µM). Our studies (Figures 2C and ON01910 on the cell cycle progression, growth, and viability of human tumor cells. We tested the activity of ON01910 against 2D) showed that increasing the concentration of the substrate resulted in increased substrate phosphorylation in the pres-94 different tumor cell lines, and interestingly, this compound was found to induce apoptosis of all of these cell lines with a ence of the inhibitor. Data analysis using the Michaelis-Menton equation (Cleland, 1977) demonstrated that the maximal veloc-GI 50 that ranged between 50-200 nM. (Selected data is shown in Table 1 .) This compound was also tested by the National ity of Plk1 was not significantly affected by the inhibitor, while the apparent values for K m were significantly increased. The Cancer Institute, through its Developmental Therapeutics Program (DTP), against their panel of 57 human cancer cell lines increase in K m , combined with unchanged V max in the presence of an inhibitor, is characteristic of competitive inhibition. The (Grever et al., 1992) . Their results showed that ON01910 had a broad-spectrum activity and inhibited the growth of all of the IC 50 values for the inhibition of Plk1 enzyme activity ( Figures  2A-2D ) demonstrate the substrate-dependent and ATP-indetested cell lines, including drug-resistant (MDR) cell lines, at nanomolar concentrations (data not shown). To further investipendent nature of inhibition. We chose to carry out these studies with HeLa cells, as they have been used extensively by several investigators to study the role of Plk1 in cell cycle progression. HeLa cells synchronized at the G1/S boundary by incubation with aphidicolin were released from G1 arrest by the removal of aphidicolin and reingate the activity of this compound against MDR-positive tumor types, we determined the IC 50 values of ON01910 using two cubation in fresh medium containing 10% FBS. Cells were classical MDR-positive, multidrug-resistant cell lines, MES-SA/ treated with DMSO or ON01910 for 8 hr, 12 hr, 16 hr, 20 hr, DX5 (Harker and Sikic, 1985) and CEM/C2 (Fujimori et al., and 28 hr following the release from G1 block and examined 1995). MES-SA/DX5 has been shown to express high levels of for Plk1 activity and cell cycle progression. Analysis of the im-P-glycoprotein and is resistant to a number of drugs, including munoprecipitates revealed that Plk1 activity is low or undetectdoxorubicin, paclitaxel, vincristine, vinblastine, etoposide, miable in control cells released from the G1/S block. This activity toxantrone, dactinomycin, and daunorubucin. The activity of increased with time and reached a peak between the 12 and ON01910 was then compared to the activity of paclitaxel 16 hr time points, and was downregulated by 20 hr ( Figure 3A ). (MDR-sensitive drug). Our results showed that while the parenPlk1 assays carried out with immunoprecipitates derived from tal cell line was very sensitive to paclitaxel (IC 50 of 4 nM), the cells treated with ON01910 showed ( Figure 3A ) that treatment MDR-positive subline was greater than 100-fold resistant (IC 50 of cells with this compound resulted in a drastic reduction of of 750 nM) to paclitaxel (data not shown). However, when the Plk1 activity at all stages of the cell cycle, indicating that this two cell lines were treated with ON01910, both the parental compound acts as potent inhibitor of Plk1 activity in vivo. Diand the MDR-positive cell lines were equally sensitive to the rect Western blot analysis of the cell lysates showed that the cell killing activity of the compound (Table 1) . ON01910 resissteady-state levels of Plk1 in both ON01910 and DMSOtance to atypical multidrug resistant cells was also investigated treated cells were low at the 0 and 8 hr time points and reached using the leukemic cell line CEM and its MDR+ subline CEM/ peak levels between 12 and 16 hr, followed by gradual down-C2 (Fujimori et al., 1995) , which is resistant to camptothecin, regulation, suggesting that the loss of Plk1 activity in etoposide, dactinimycin, bleomycin, mitoxantrone, doxorubicin, ON01910-treated cells is not due to degradation of Plk1 or inand daunorubicin. Our results again showed that CEM/C2 was hibition of Plk1 synthesis. In DMSO-treated cells, cyclin B1 highly sensitive to ON01910, suggesting that this compound levels were upregulated between 12 and 16 hr, followed by does not share any crossresistance to classical MDR and atyprapid downregulation as the cells exited mitosis followed by ical MDR cell lines (Table 1) .
the onset of cytokinesis ( Figure 3A ). In cells treated with ON01910, cyclin B1 levels accumulated between 12 and 16 hr In vivo inhibition of Plk1 activity by ON01910 and failed to be downregulated, suggesting a block in mitotic Because Plk1 has been shown to be essential for progression through mitosis and cytokinesis of many tumor cell lines, it was progression and cytokinesis. The slightly lower levels of cyclin B1 seen at the 28 hr time point appear to be due to the onset confocal microscopy. HeLa cells blocked at the G1/S interphase with aphidicolin were released from G1 arrest, treated of apoptotic death in these cells. Measurement of CDK1 activity in control and 1910-treated cells revealed that like Plk1 acwith DMSO or ON01910 (250 nM) for 7 or 12 hr, fixed with 4% paraformaldehyde, and treated with FITC-conjugated antitivity, CDK1 activity was low in cells released from the aphidicolin block, increased with time, reached a peak around the 16 α-tubulin antibody (to visualize tubulin spindles) and propidium iodide (to visualize chromosomal DNA). Confocal laser microhr time point, and was downregulated by the 20 hr time point. ON01910-treated cells exhibited a slightly lower level of CDK1 scopy of the stained cells ( Figure 4A ) showed that while DMSO-treated cells go through various phases of mitosis withactivity, suggesting that this compound inhibits CDK1 activity, albeit with much lower potency than Plk1.
out any abnormality, ON01910-treated cells exhibit profound abnormalities in spindle formation, resulting in the appearance of multipolar spindles, which leads to misalignment of chromoEffect of ON01910 on cell cycle progression of human tumor cells somes and complete loss of coordination in mitotic spindle assembly. In ON01910-treated cells, the chromosomes do not Flow cytometric analysis of HeLa cells ( Figure 3B ) from the above set of experiments showed that control cells released seem to be stably attached to the spindle, similar to the phenotype observed with Plk1-depleted cells (Sumara et al., 2004) . from the aphidicolin block synchronously transited through S phase and entered the G2/M phase between the 12 and 16 hr It is now known that Plk1 localizes to centrosomes during interphase and participates in microtubule dynamics. Plk1-time points. This was followed by cytokinesis and reentry of cells into the G1 phase between the 16 hr and 20 hr time depleted HeLa cells show abnormal localization of γ-tubulin, with centrosomes often depleted of γ-tubulin (Sumara et al., points. It is interesting to note that Plk1 levels persist in cells that have gone through cytokinesis, consistent with previously 2004). To determine the effects of ON01910 on centrosome dynamics, HeLa cells incubated with DMSO or ON01910 for 7 published observations (Golsteyn et al., 1994) . Incubation of HeLa cells with ON01910 following release from the aphidicolin or 12 hr (as described above) were stained with antibodies to γ-tubulin and propidium iodide. As expected, in control cells, block resulted in the accumulation of cells in the G2/M phase of the cell cycle between 8 and 16 hr, followed by rapid loss of γ-tubulin antibodies stained centrosomes that formed the center of the spindle poles, which could be visualized at the 7 hr viability. These results strongly suggest that ON01910-mediated mitotic arrest leads to tumor cell death.
and 12 hr time points following the release from the aphidicolin block ( Figure 4B ). In sharp contrast, in cells treated with We next investigated the effect of ON01910 on several normal human cell lines, which included fibroblastic cells as well ON01910, these antibodies stained multiple centriole pairs, which seem to be randomly distributed in the area of the spinas epithelial cell lines. Interestingly, these cell lines were found to be very resistant to the apoptotic effects of ON01910, which dle, or even outside of it. Following a 12 hr incubation in the presence ON01910, degradation of these γ-tublin-positive induced cell death only at 5-10 µM concentration (Table 1 and Supplemental Figure S2 ). When human fibloblastic cells (HFLs) structures could be readily visualized ( Figure 4B ). These observations suggest that exposure of tumor cells to ON01910 rewere subjected to cell cycle analysis, both control and ON01910-treated cells progressed through mitosis without any sults in abnormal centrosome localization and fragmentation, which could be due to Plk1 inhibition. abnormality, suggesting that ON01910 fails to block their cell cycle progression (Supplemental Figure S2B) . It is interesting A consequence of the mitotic abnormalities induced by this agent could be the activation of apoptotic pathways in to note that previous studies using anti-sense oligonucleotides and small interfering RNAs directed against PLK1 showed that ON01910-treated cells. To verify this possibility, HeLa cells treated with DMSO or ON01910 for 0, 24, and 48 hr were subthese agents, while readily blocking tumor cell cycle progression, failed to block cell cycle progression of normal fibrojected to annexin V and propidium iodide staining followed by flow cytometric analysis. As can be seen in Figure 5A , DMSOblasts and epithelial cell lines (Spankuch-Schmitt et al., 2002b) . These results suggest the possibility that inhibition of PLK1 actreated cells remain double-negative and hence viable at the 24 and 48 hr time points. On the other hand, cells treated with tivity is more detrimental to tumor cells than normal cells. This could be due to the compensatory effects of other Plk family ON01910 become annexin V-positive within 24 hr and become double-positive within 48 hr of incubation, suggesting a rapid members in normal cells, a process that might be inoperative in tumor cells.
onset of apoptosis in these cells. The activation of apoptotic pathways could also be demonstrated by examining PARP (Poly[ADP-ribose] polymerase-1) cleavage (Soldani and ScoEffect of ON01910 on spindle assembly and cytokinesis Plk1 is now known to be concentrated at the centrosomal revassi, 2002), which is a marker for caspase activation. Western blot analysis of HeLa cell lysates treated with DMSO or gion during interphase, and as cell cycle progression occurs, it associates with mitotic spindle poles. From metaphase on-ON01910 ( Figure 5B ) show PARP cleavage in ON01910-treated cells as early as 24 hr, which becomes very pronounced by 48 ward, Plk1 relocates to the midzone, from which the midbody is eventually derived, as the cell goes through telophase hr, indicating the progression of apoptosis in these cells. Analysis of cell lysates for Caspase-3 activity also revealed a dra- Wianny et al., 1998; Barr et al., 2004) . Plk1-depleted HeLa cells were found to enter matic upregulation of this activity in ON01910-treated cells ( Figure 5C ). mitosis, but accumulated in a preanaphase state characterized by spindles that lacked focused poles and were not attached To rule out the possibility that the chromosomal abnormalities induced by ON01910 are due to direct binding to β-tubuto centrosomes (Sumara et al., 2004) . The chromosomes themselves also did not become stably attached to the spindle (Sulins and thereby interfering with its polymerization or depolymerization, we conducted in vitro polymerization reactions using mara et al., 2004) . To test whether ON01910 induces spindle abnormalities, we examined the spindle architecture using ON01910. In these studies, paclitaxel, which stabilizes tubulin polymerization, and vinblastine, which induces tubulin depoper week for 4 weeks was well tolerated. In dogs, acute single doses of 2000 and 4000 mg/m 2 produced gastrointestinal eflymerization, were used as controls. For these assays, purified bovine tubulin was incubated with GTP at 37°C in the presence fects (diarrhea, flatulence), with other signs of discomfort during dosing at 4000 mg/m 2 (struggling, vocalization). In 7 day of DMSO or different compounds dissolved in DMSO, and tubulin polymerization was detected by measuring the absorrepeat i.v. dosing, 1000 mg/m 2 daily was well tolerated by dogs. In 28 day repeat dosing, daily intravenous doses of 200 bance of the solution at 340 nm over time. The results of this study ( Figure 5D ) show that ON01910 had no effect on the and 500 mg/m 2 were well tolerated for 28 days in groups consisting of 3 male and 3 female beagle dogs. A high dose group kinetics of tubulin polymerization, while the addition of vinblastine inhibited tubulin polymerization and paclitaxel enhanced started at 1000 mg/m 2 showed no signs of toxicity after 8 days. Based on dose escalation studies, a highest non-severe toxic the polymerization. dose for this dose schedule was estimated at about 1500 to Safety pharmacology 2000 mg/m 2 for 28 days. A separate group of 6 dogs treated The safety profile of ON01910 was determined in two standard at 1000 mg/m 2 twice per week for 4 weeks tolerated the comtoxicology animal studies using rats and dogs (Table 2 ). In rats, pound well without clinical problems. There was no evidence of single doses of 300 and 600 mg/m 2 produced no toxicity, and significant myelotoxicity, neuropathy, or cardiotoxicity in these 1200 mg/m 2 had only slight toxicity (anogenital staining). When toxicology studies. the dose was increased to 3000 mg/m 2 , 9 of 11 animals died. In 7 day repeat dosing (1200 mg/m 2 ), 2 of 13 rats died during
Effects of ON01910 on tumor growth in nude mice
We next tested the in vivo antitumor activity of ON01910 using the dosing period. In 28 day repeat dosing, using groups of 12 male and 12 female rats, fixed daily doses of 180 mg/m 2 and the nude mouse model system. Female athymic (NCr-nu/nu) mice were injected subcutaneously with 1 × 10 7 Bel-7402, 450 mg/m 2 were tolerated. A dose of 900 mg/m 2 given twice MCF-7, or MIA PaCa human tumor cells derived from human sented in Figures 6A, 6C , and 6E show that ON01910 readily inhibited tumor growth in these xenograft model systems. In liver, breast, and pancreatic cancers, respectively, and the tumors allowed to grow for 7-10 days to a size of 200-250 mm.
all three cases, ON01910 had a better effect than the three therapeutic agents used for comparison. More importantly, The mice were then divided into four groups, of which one group received a dose of the vehicle alone and a second group there was no evidence of toxicity as judged by body weights ( Figures 6B, 6D , and 6F). Bone marrow colony assays from received a dose of ON01910. In the case of the Bel-7402 tumors, the third group received a dose of oxaliplatin and the ON01910-treated animals showed no decrease in colony formation (data not shown). Most interestingly, treatment of tufourth group a combination of ON01910 and oxaliplatin. The tumor size and total body weights were then measured weekly mor-bearing mice with a combination of ON01910 and oxaliplatin or doxorubicin resulted in complete disappearance of as described in the Experimental Procedures. In the case of MCF-7-derived tumors, doxorubicin was used instead of oxathe tumor mass in these animals. Treatment with a combination of gemcitabine and ON01910 resulted in a substantial deliplatin. MIA PaCa-derived tumors were treated with ON01910 or gemcitabine or a combination of ON01910 and gemcitabine crease in tumor mass. To further verify the activity of ON01910, the tumor masses from one control mouse (treated with PBS) as described in Experimental Procedures, and tumor volumes and body weights determined every third day. The results preand two experimental animals (treated with ON01910) were re- moved at the end of 21 days of treatment and tumor extracts the centrosome's microtubule nucleating activity upon mitotic entry, and mutation or inhibition of Plk1 results in aberrations prepared and analyzed for Plk1 and CDK1/Cyclin B1 activities. The data presented in Figure 6G show that the control tumor in mitotic spindle formation Barr et al., 2004) . Plk1-depleted cells enter mitosis, but accumulate in a cell lysates exhibit very robust Plk1 and CDK1 activities, while the tumor cell lysates derived from the ON01910-treated mice preanaphase state replete with spindle abnormalities characterized by the absence of focused poles, and chromosomes had little or no Plk1 activity. CDK1 activity in the ON01910-treated samples was reduced, but not completely eliminated.
that do not become stably attached to the spindle (Sumara et al., 2004) . Plk1 also appears to facilitate recruitment of γ-tubuDirect Western blot analyses revealed that tumor extracts from both control and ON01910-treated animals had similar steadylin and activation of Asp at the centrosome, which helps focus the microtubule ends and maintain their proximity to the state levels of these two proteins. The low toxicity profile and potent tumor inhibitory activity seen in nude mouse xenograft centrosome Barr et al., 2004) . Plk1 is also known to activate certain functions of the anaphase-promoting assays points to the potential value of ON01910 as a safe therapy for cancer. complex (APC), which triggers the destruction of Cyclin B, allowing mitotic exit (Barr et al., 2004; Lane and Nigg, 1996; Kotani et al., 1998) . The concept that Plk1 is a potential target for Discussion cancer therapy has been substantiated by the observations that suppression of Plk1 expression or activity by anti-sense Recent strides made in our understanding of the molecular oligonucleotides or siRNAs or dominant negative mutants inchanges that accompany cell transformation have established duces programmed cell death in human tumors, which is often that cancer is the result of alterations in multiple signal transpreceded by abnormal spindle formation (Lane and Nigg, 1996 ; duction pathways. Drugs such as imatinib (also known as Cogswell et al., 2000; Spankuch-Schmitt et al., 2002a; SpanGleevec or STI571) , an inhibitor of the BCR-ABL tyrosine kinase (Druker and Lydon, 2000) , has been a great success.
kuch- Schmitt et al., 2002b; Liu and Erikson, 2003; Sumara et al., 2004) . Such drugs have a very targeted application in the treatment of a specific form of cancer with a mutation that is unique to By developing small molecule inhibitors of Plk1 which target regions outside the ATP binding site, we may avoid one of the that cancer. In addition to BCR-ABL, imatinib has also been found to be a potent inhibitor of PDGF receptor (PDGFR) and anticipated problems associated with kinase inhibitors, the development of drug resistance as a result of accumulating c-Kit (reviewed in Druker and Lydon, 2000; Sawyers, 2004) . This crossreactivity may reflect the close structural similarity in mutations in the ATP binding site of the kinase, as has been observed in patients undergoing treatment with imatinib (Sawthe ATP binding pockets of these different kinases, which has provided new applications for this drug in the treatment of canyers, 2004) . Because selection of highly conserved mutable residues in the ATP binding site appears to be relatively comcers where abnormalities in PDGFR and c-Kit expression play a critical role (Sawyers, 2004) . mon for many kinases, it has been argued that substrate-competitive inhibitors might constitute better drug candidates (LevBecause all signaling pathways that have gone awry in a cancer cell ultimately affect cell cycle progression, an alternaitzki, 2000). In addition, many of the kinase inhibitors that are ATP mimetics inhibit their enzyme targets at nanomolar contive approach for cancer therapy is to develop inhibitors that block the function of a critical molecule that is required by a centrations, while requiring micromolar concentration for tumor cell growth inhibition, and this discrepancy may be related to tumor cell to complete cell division. One such molecule appears to be Plk1. Named after the Drosophila polo gene, which the need to overcome millimolar concentrations of ATP known to exist inside the cell (Levitzki, 2000) . The results presented in was identified through a recessive maternal effect lethal mutation, this gene family is highly conserved throughout evolution this study describe the identification of a novel pharmacophore, which inhibits Plk1 at a 9-10 nM concentration and is from yeast to man and plays a critical role in centrosome maturation, progression through mitosis, and the onset of cytokinenoncompetitive to ATP. It is likely that this compound binds to Plk1 at or near the substrate binding domain, since substrates sis (Golsteyn et al., 1994; Glover et al., 1996; Wianny et al., 1998; Barr et al., 2004; Dai and Cogswell, of Plk1 compete for the inhibitory activity of ON01910. In addition to Plk1, ON01910 was also inhibitory to Abl, Flt-1, and 2003). In human cells, it has been shown that Plk1 stimulates A: Nude mouse xenograft assays using Bel-7402 human tumor cells was carried out using ON01910 or oxaliplatin or a combination of the two compounds, and tumor sizes measured weekly and the volume determined as described in the Experimental Procedures. B: Total body weight of individual mice in the four groups was determined weekly and the average body weights plotted. C: Nude mouse xenograft assays using MCF-7 human tumor cells using doxorubicin or ON01910 or a combination of the two compounds were carried out, and tumor sizes measured weekly and the volume determined as described in the Experimental Procedures. D: Total body weight of individual mice in the four groups was determined weekly and the average body weights plotted. E: Nude mouse xenograft assays using human pancreatic tumor cells MIA-PaCa was carried out using ON01910 or gemcitabine or a combination of the two compounds, and tumor sizes measured biweekly and the volume determined as described in the Experimental Procedures. F: Total body weight of individual mice in the four groups was determined biweekly and the average body weights plotted. The data in A, C, and E represent average tumor volume ± SEM, and the data in B, D and F represent average body weight ± SEM G: Tumors excised from one control mouse (lane C) and two experimental animals treated with ON01910 (lanes 2 and 8) were minced and homogenized in modified RIPA buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 1 mM PMSF, 1% Triton X100, and a cocktail of protease inhibitors; Roche Applied Science, Indianapolis) and clarified by centrifugation at 13,000 × g for 15 min at 4°C. The supernatants were immunoprecipitated with antibodies directed against Plk1 or Cyclin B1 and the immunoprecipitates used to carry out kinase assays using casein or Histone H1 as substrates, as described in Figure 3 . Direct Western blot analysis of the tumor lysates was performed using 50 µg of the total protein.
Analysis of cell cycle progression and apoptosis
PDGFR kinases at low nanomolar concentrations. At approxiHeLa cells were synchronized at the G1/S boundary by aphidicolin block mately 10-to 20-fold higher concentrations, inhibition of Src, as described by Heintz et al. (1983) . Briefly, exponentially growing cells were Fyn, and Plk2 kinases was also observed. While it is possible treated with aphidicholin (1 µg/ml, Sigma) for 14 hr followed by washing that inhibition of these kinases may play a role in the phenothrice with normal growth medium and incubation in the presence or abtype observed in ON01910-treated cells, the fact that this comsence of ONO1910. At the indicated intervals, cells were collected by trypsinization, washed with PBS, fixed in 70% ethanol, incubated with propidpound is most active against Plk1 suggests that this enzyme ium iodine (50 ug/ml) and RNase A (0.5 mg) for 30 min, and analyzed on a is the primary target of this compound.
Becton-Dickinson (BD) (FACScan) flow cytometer. Staining with FITC-ON01910 induces mitotic arrest in a wide variety of human Annexin V was carried out as described by the manufacturer (BD Bioscitumor cells, characterized by spindle abnormalities leading to ences). PARP cleavage assays were performed with equal amounts of total their apoptotic death. Most interestingly, MDR-positive cells, cellular proteins that were resolved on a 10%-SDS-polyacrylamide gel, and Western blotting analysis performed using anti-PARP antibodies (BD Biosciwhich are resistant to many commonly used chemotherapeutic ences). Caspase 3 activity was measured using a commercial caspase-3 agents, were nevertheless very sensitive to the activity of this assay kit (CaspACE, Promega, Madison, WI). Caspase enzymatic hydrolysis compound. Because mutations in the ATP binding site appear was measured by pNA liberation from Ac-DEVD-pNA upon cleavage by to be relatively common for many kinases, we tested whether DEVDase at 405 nm using a spectrophotometer.
we could select for resistance to ON01910 in tumor cells by culturing them in the presence of sublethal amounts of the Tubulin polymerization assays Tubulin polymerization assays were performed using the Tubulin Polymercompound. In these experiments, we could isolate cell lines ON01910 produced no toxicity, and 1200 mg/m 2 had only slight toxicity. There was no evidence of significant myelotoxiIn vitro enzyme assays for Plk1 city, neuropathy, or cardiotoxicity in these toxicology studies.
Plk1 expressed in the Sf9 cell line was purified as described by Lee and Erikson (1997) resulting in complete remission of the tumors in xenograft substrates. Reactions were terminated by boiling for 2 min in 20 µl of 2× Laemmli buffer (Laemmli, 1970) . Phosphorylated substrates were separated model systems.
by 18% SDS-PAGE (Laemmli, 1970) . The gels were dried and exposed to The low in vivo toxicity and the potent tumor inhibitory activ-X-ray film for 3-10 min.
ity seen in nude mouse xenograft assays (i.e., a high therapeutic index) led to Phase I trials of ON01910, which are currently Filter binding assays for Plk1 in progress. Because this compound is highly effective in variPlk1 assays were performed as above. After incubation, 10 µl aliquots of ous combinations with conventional chemotherapy, the lack of the reaction mixture were spotted onto a P81 phosphocellulose paper. The filters were washed 3 times for 5 min each with 0.75% phosphoric acid bone marrow toxicity may be beneficial for testing novel comfollowed by acetone, and the radioactivity determined using a liquid scintilbinations for advanced cancers, including tumors resistant to lation counter. Control samples contained appropriate amounts of DMSO.
conventional chemotherapy. Clinical studies, which are currently mental values. The kinase activity is expressed as a percent of the maximal kinase activity. Dose response curves were used for calculating IC 50 values.
Experimental procedures
All assays were carried out in triplicate.
Cell culture and viability assays
In vitro assays for Plk1 and CDK1 using cell lysates ON01910 was synthesized in the laboratory, and its purity and structure Cells were washed with PBS and lysed in lysis buffer (25 mm HEPES, 0.1% were confirmed by HPLC, melting points, and NMR. Paclitaxel was Triton-X-100, 300 mM NaCl, 0.5 mM DTT, 0.2 mM Na 3 VO 4 , 0.2 mm EDTA, purchased from Sigma. All cell lines were grown in DMEM or RPMI (Cellgro), 1.5 mM MgCl 2 , 20 mm β-glycerophosphate and protease inhibitor cocktail). supplemented with 10% fetal bovine serum (Atlas Co) and 1 unit/ml of peniFollowing high-speed centrifugation, the cell lysates were used for various cillin-streptomycin. Cell viability assays were performed by incubation in the kinase assays. For CDK1 assays, 100 g of total protein was incubated presence of the drug for 96 hr and the number of viable cells determined with 5 g of anti-CDK1 or anti-cyclin B1, antibodies, and protein A agarose for 2 hr at 4°C. The protein complexes were washed three times with lysis by trypan blue exclusion.
